Journal Article (Review Article)

DZNE-2023-00727

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Predicting cognitive decline in older people by structural and molecular imaging.

Teipel, S. (First author)DZNE* ; Tang, Y. ; Boccardi, M. (Last author)DZNE*

2023
Ovid

This record in other databases:    

Please use a persistent id in citations: doi:10.1097/WCO.0000000000001172

Abstract: Availability of possible disease modifying treatments and the recognition of predementia stages of Alzheimer's disease (AD) have raised awareness for the prognostic and predictive role of biomarkers, particularly imaging markers.The positive predictive value of amyloid PET for the transition to prodromal AD or AD dementia in cognitively normal people is below 25%. Evidence for tau PET, FDG-PET and structural MRI is even more limited. In people with mild cognitive impairment (MCI), imaging markers yield positive predictive values above 60% with moderate advantages for amyloid PET over the other modalities and an added value for the combination of molecular with downstream neurodegeneration markers.In cognitively normal people, imaging is not recommended for individual prognosis due to lack of sufficient predictive accuracy. Such measures should be restricted to risk enrichment in clinical trials. In people with MCI, amyloid PET and, to a somewhat lesser extent, tau PET, FDG-PET, and MRI yield relevant predictive accuracy for clinical counseling as part of a comprehensive diagnostic program in tertiary care units. Future studies should focus on the systematic and patient-centered implementation of imaging markers in evidence-based care-pathways for people with prodromal AD.

Keyword(s): Humans (MeSH) ; Aged (MeSH) ; Fluorodeoxyglucose F18 (MeSH) ; Alzheimer Disease: diagnostic imaging (MeSH) ; Cognitive Dysfunction: diagnostic imaging (MeSH) ; Prognosis (MeSH) ; Positron-Emission Tomography: methods (MeSH) ; Biomarkers (MeSH) ; Molecular Imaging (MeSH) ; Amyloid beta-Peptides (MeSH) ; tau Proteins (MeSH) ; Fluorodeoxyglucose F18 ; Biomarkers ; Amyloid beta-Peptides ; tau Proteins

---

Contributing Institute(s):

1. Implementation Neuroscience (AG Boccardi)
2. Clinical Dementia Research (Rostock /Greifswald) (AG Teipel)

Research Program(s):

1. 353 - Clinical and Health Care Research (POF4-353) (POF4-353)

Appears in the scientific report 2023

---

Database coverage:
; Allianz-Lizenz ; BIOSIS Previews ; BIOSIS Reviews Reports And Meetings ; Clarivate Analytics Master Journal List ; Current Contents - Clinical Medicine ; Essential Science Indicators ; IF < 5 ; JCR ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection

---